Clinical trials: Controlled Hypertension
Diabetes Mellitus, Type 2, Hypertension
Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents
The purpose of this study is to evaluate the effect of canagliflozin (JNJ-28431754) on blood pressure reduction, compared to placebo, in patients with hypertension and type 2 diabetes mellitus and who are on stable doses of…
- Trial name
- NCT01939496
- Testing
- Canagliflozin
- Where
- 57 sites in United States, Puerto Rico
- Volunteers
- 171 people
- Sponsor
- Janssen Scientific Affairs, LLC
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Safety and Effectiveness of PRX-08066 in Patients With Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease
This study is being conducted to see if PRX-08066 can lower pulmonary artery pressures in patients with pulmonary hypertension associated with chronic obstructive pulmonary disease.
- Trial name
- NCT00345774
- Testing
- PRX-08066
- Where
- 19 sites in United States
- Volunteers
- 72 people
- Sponsor
- Epix Pharmaceuticals, Inc.
Cataract, Glaucoma
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)
This trial is a randomized study to evaluate the Bimatoprost Implant System used in combination with the SpyGlass IOL to Timolol Ophthalmic Solution in participants with mild to moderate open-angle glaucoma or ocular hypertension…
- Conditions
- Cataract, Glaucoma, Ocular Hypertension
- Trial name
- NCT07218796
- Testing
- Bimatoprost Implant System, SpyGlass IOL, Timolol Maleate Ophthalmic Solution, 0.5%
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- SpyGlass Pharma, Inc.
Hypertension Emergency, End-organ Damage
Post Marketing Study to Evaluate the Two Dose Regimens of Nicardipine Injection in Hypertensive Emergency Patients
To compare the efficacy and safety of two dose adjustment regimens (i.e. weight-based and non-weight-based) for the treatment of Chinese hypertensive emergency patients.
- Trial name
- NCT01872039
- Testing
- Perdipine injection
- Where
- 5 sites in China
- Volunteers
- 163 people
- Sponsor
- Astellas Pharma China, Inc.
Hypertension
Study of the Efficacy and Safety of Nebivolol in Younger Patients (18 - 54 Years)
The purpose of this study is to assess the efficacy, safety, and tolerability of 8 weeks of therapy with nebivolol in comparison to placebo in younger patients 18 - 54 years of age with stage 1 or stage 2 essential hypertension.
- Trial name
- NCT01415531
- Testing
- Nebivolol
- Where
- 75 sites in United States
- Volunteers
- 641 people
- Sponsor
- Forest Laboratories
Hypertension
A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients
The purpose of this study is to evaluate the efficacy, safety and tolerability of QCZ484 or placebo, given subcutaneously, every 6 months, at different dose levels in patients with mild to moderate hypertension
- Trial name
- NCT06857955
- Testing
- Saline, QCZ484
- Where
- 72 sites in United States, Japan and 1 more
- Volunteers
- 396 people
- Sponsor
- Novartis Pharmaceuticals
Uncontrolled Hypertension
A Study of CIN-107 in Patients With Uncontrolled Hypertension
This is a Phase 2, randomized, multicenter study to evaluate the efficacy and safety of multiple dose strengths of baxdrostat (also called CIN-107) in the treatment of patients with uncontrolled hypertension.
- Trial name
- HALO (NCT05137002)
- Testing
- CIN-107
- Where
- 63 sites in United States
- Volunteers
- 249 people
- Sponsor
- CinCor Pharma, Inc.
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)
This protocol is for subjects with pulmonary arterial hypertension and is the first of 3 studies forming the Sitaxsentan efficacy and safety trial with Randomized Prospective Assessment of Adding Sildenafil (SR-PAAS) program.
- Trial name
- NCT00795639
- Testing
- Sitaxsentan
- Where
- 85 sites in United States, Argentina and 22 more
- Volunteers
- 183 people
- Sponsor
- Pfizer
Hypertension
Post-marketing Study to Supplement Data on Safety, Tolerability and Efficacy of Micardis® With Special Emphasis on the Control of Blood Pressure
This post-marketing surveillance study is designed to supplement under conditions of normal clinical practice data on safety, tolerability and efficacy of Micardis® collected in clinical studies with special emphasis on the…
- Trial name
- NCT02242331
- Testing
- Micardis®
- Volunteers
- 19,805 people
- Sponsor
- Boehringer Ingelheim
Glaucoma
Safety, Efficacy Assessment of Geltim LP® 1 mg/g in Ocular Hypertensive or Glaucomatous Patients.
This phase IV study aims to assess the safety and the efficacy in intra ocular pressure of Geltim LP® 1 mg/g (0.1% unpreserved timolol maleate gel) in glaucomatous patients initially treated and stabilised by monotherapy of…
- Trial name
- T1030 (NCT01155219)
- Testing
- Geltim LP 1 mg/g, Xalatan
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Laboratoires Thea
Hypertension
A Study to Investigate Efficacy and Safety of a TCA108 in Participants ≥18 Years With Uncontrolled Hypertension
The purpose of this study if to evaluate the efficacy and safety of TCA108 on treatment of hypertension.
- Trial name
- TRÍADE-HA (NCT07030101)
- Testing
- TCA108, Bramicar HCT, Micardis Anlo
- Volunteers
- 400 people
- Sponsor
- EMS
Arterial Hypertension
Efficacy and Safety of Olmesartan Associated With Chlorthalidone Versus Benicar HCT® in Essential Hypertension Control
The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the essential hypertension control.
- Trial name
- NCT02483936
- Testing
- Olmesartan medoxomil 40mg + chlorthalidone 12,5mg, Olmesartan medoxomil 40mg + chlorthalidone 25mg, Olmesartan 40mg + Hydrochlorothiazide 12,5mg
- Sponsor
- EMS
Essential Hypertension
A Phase III Study to Efficacy and Safety of DWC202405/DWC202313 and DWC202314 in Patients With Hypertension
A Multi-center, Randomized, Double-blind, Parallel design, Phase III study to Evaluate and Compare the Efficacy and Safety of DWC202405/DWC202313 and DWC202314 Combination Therapy to DWC202405/DWC202313 in Patients with Essential…
- Trial name
- NCT06671392
- Testing
- DWC202405, DWC202405, DWC202314, DWC202405, DWC202314P
- Where
- South Korea
- Volunteers
- 198 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Patients, Resistant Hypertension
Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients
The purpose of the present study was to determine whether LHW090 displays the clinical safety and efficacy profile to support further development in patients with resistant hypertension.
- Trial name
- NCT02515331
- Testing
- LHW090
- Where
- 16 sites in United States, Denmark and 4 more
- Volunteers
- 64 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2
Evaluation of the Integrated Radio Frequency Denervation System to Improve Glycemic Control in Type 2 Diabetic Subjects
The objective of this early feasibility study is to evaluate the safety and performance of intravascular hepatic denervation using the Metavention Integrated Radio Frequency Denervation System (iRF System) to improve glycemic…
- Trial name
- DeLIVER (NCT04285554)
- Testing
- iRF System Hepatic Denervation
- Where
- 8 sites in United States
- Volunteers
- 15 people
- Sponsor
- Metavention
Pulmonary Arterial Hypertension
A Study of RVT-1201 in Patients With Pulmonary Arterial Hypertension (ELEVATE 1)
This is an exploratory Phase 2a, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of RVT-1201 in patients with…
- Trial name
- NCT03924154
- Testing
- RVT-1201
- Where
- 23 sites in United States, Canada
- Volunteers
- 3 people
- Sponsor
- Altavant Sciences GmbH
Pulmonary Fibrosis, Pulmonary Hypertension
A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis at Risk for Pulmonary Hypertension
A randomized, double-blind, placebo-controlled dose escalation and verification study to assess the safety and efficacy of pulsed inhaled nitric oxide (iNO) in subjects at risk for pulmonary hypertension associated with pulmonary…
- Trial name
- REBUILD (NCT03267108)
- Testing
- INOpulse®, Open Label Extension
- Where
- 64 sites in United States, Canada
- Volunteers
- 145 people
- Sponsor
- Bellerophon Pulse Technologies
Hypertension
A Long-term Study of the Safety of MK-0954A in Patients With Essential Hypertension (MK-0954A-351)
This study is being conducted to evaluate the safety of MK-0954A (L100/H12.5 mg) in essential hypertension participants who are uncontrolled with MK-954H (L50/H12.5 mg).
- Trial name
- NCT01307033
- Testing
- MK-0954A, MK-954H
- Volunteers
- 278 people
- Sponsor
- Organon and Co
Essential Hypertension
Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Early Morning Blood Pressure and Central Arterial Pressure
The purpose of this study is to compare nifedipine controlled-release (CR) tablets (Xin Ran) with nifedipine controlled-release tablets (Adalat）in the treatment of Early Morning Blood Pressure and Central Arterial Pressure.
- Trial name
- NCT02357615
- Testing
- nifedipine CR tablets (Xin Ran), Adalat
- Where
- China
- Volunteers
- 244 people
- Sponsor
- Shanghai Shyndec Pharmaceutical Co., Ltd.
Hypertension
TARGET BP I Clinical Trial
The TARGET BP I Trial is a randomized, blinded, multi-center, international, sham-procedure controlled trial, comparing renal denervation performed with the Peregrine System Kit in the treatment group to the sham control group…
- Trial name
- TARGET BP I (NCT02910414)
- Testing
- Dehydrated alcohol
- Where
- 5 sites in United States
- Volunteers
- 300 people
- Sponsor
- Ablative Solutions, Inc.